A Phase 1 Study of the Highly-selective RET

This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated dose(MTD) of Blu-667 and recommend a dosage for Phase 2 portion of the trial

You may be eligible for this study if you meet the following criteria:

• Conditions:
  ['RET-altered Non Small Cell Lung Cancer', 'Medullary Thyroid Cancer', 'RET-altered Papillary Thyroid Cancer', 'RET-altered Colon Cancer', 'RET-altered Solid Tumors']
• Age: - 99 Years
• Gender: All